Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Kadimastem Earns FDA Approval of its IND Application For its US Multi-Site Phase IIa Clinical Trial of AstroRx® to Treat ALS

Kadimastem Ltd.

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic cell products using its platform technology to develop treatments for different neurodegenerative diseases and a potential cure for diabetes, has received FDA clearance to commence a phase IIa clinical trial in the US according to the Investigational New Drug (IND) application that was submitted in February 2023. The trial will test its lead neurological cell therapy product AstroRx ® in repeated dosing of three-month intervals for the treatment of patients with ALS. The planned clinical trial follows a first in human phase I/IIa clinical trial previously conducted by the company in Israel, in which AstroRx® was injected into the spinal cord fluid using a standard lumbar puncture procedure. In this phase I/IIa clinical trial Kadimastem demonstrated a good safety profile and clinically meaningful decline in the disease progression during the first 3-months follow-up period. AstroRx® contains functional, healthy astrocytes (nervous system supporting cells) differentiated from human Embryonic Stem Cells (hESC) that aim to support the survival of diseased motor neurons through several mechanisms of action. The treatment’s goal is to nourish and support the malfunctioning motor neurons in the brain and spinal cord of patients suffering from Amyotrophic Lateral Sclerosis (ALS), to significantly slow the progression of the disease and improve the quality of life and life expectancy of the treated patients. Kadimastem CEO Asaf Shiloni said, “The FDA approval for this multi-site clinical trial is a major achievement for us and is a recognition of our professional, clinical and scientific abilities. I’d like to congratulate our dedicated team on this extremely important landmark, which is an enormous milestone that brings great hope for the future of the ALS patients as well as our supporters and investors.” Kadimastem Founder and Chief Scientific Officer Professor Michel Revel said, “The approval of submission of the IND to the FDA is a major achievement and moment of pride for me in the company that I have founded years ago, with an amazing team. It is very exciting, and we eagerly await to start this trial and wish to help ALS patients as soon as possible.” About AstroRx ® & ALS Kadimastem’s flagship product, AstroRx®, is a breakthrough technology that is comprised of a unique and large cell population of astrocytes derived from human pluripotent stem cells. The cells are intended to support the survival of motoneurons (neurons the control the motor-capability) in the central nervous system (CNS, brain and spinal cord). AstroRx® enables the transplantation of healthy astrocytes into the CNS of the ALS patient and an improvement in the protection of the motoneurons. In December 2020, Kadimastem announced the results Kadimastem (TASE:KDST) is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical needs. of the first of its kind, Phase I/IIa clinical trial, in which healthy and functioning astrocyte cells (AstroRx®) were injected into the spinal fluid of 10 ALS patients. Data showed that AstroRx® has the potential to slow the progression of ALS, as indicated by a clinical score called ALSFRS-R. Kadimastem plans to test repeated doses every three months of AstroRx® to achieve a continuous delay of the disease. This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1601 s.bazak@kadimastem.com GOTLIVE Media Group Lior Gottlieb +972 50-920-0194 lior@gotlive-ir.co.il Company Website https://www.kadimastem.com/

March 20, 2023 07:00 AM Eastern Daylight Time

UAT Group Subsidiary, Ossifix Orthopedics Begins Expansion

Umbra Applied Technologies Group, Inc.

McapMediaWire -- Umbra Applied Technologies Group, Inc. (OTC: UATG ) (UAT Group) announced today that its subsidiary, Ossifix Orthopedics has begun expanding beyond Texas starting with southern and north-eastern part of the United States. Over the past several weeks, the Company has onboarded five new account managers across eleven cities in Texas with expansion into the New England area currently underway. The Company has slated the second fiscal quarter of the year for expansion across four major metropolitan cities in Louisiana and across twenty-one major metropolitan cities in Florida. Ossifix CEO, Mark Estrada, stated: “We are currently in the process of expanding operations and onboarding distribution channels in select target regions. Additionally, in Q2 we will launch two unique foot and ankle product lines.” The Company projects more than one-hundred surgeries to be completed in Q2 alone with a 20% increase month over in growth. Results from initial surgeries have demonstrated early ambulation trend with many patients driving the next day. Results of the surgeries have dramatically increased interest in the Javelin pin which formed the basis for the Company’s decision to start expansion and led to the Company to begin increasing its salesforce. Constructed of select, high-density, allograft, cortical bone, the proprietary design of the Ossifix Orthopedics Javelin pin ensures rigid fixation without pin slip or pirouetting. Manufactured of 100% allograft bone, Ossifix implants are designed for small bone, extremities, and sports medicine markets, but have applications in the craniofacial, spine and oral surgery procedures. Resorbable implant technology is readily accepted and used in today’s market, both domestically and globally. Ossifixs’ unique manufacturing process and designs yield an engineered cortical bone implant that provides secure fixation and virtually eliminates any allergic or autoimmune reactions associated with metal or plastic/polymer implants. All Ossifix Orthopedics Pin, Screw and Plate Systems are single-use surgical kits with all necessary instruments for implantation and are based on decades of clinical experience and use in the operating room. Ossifix products are designed to be used in hospitals, ambulatory surgical centers, and specialty clinics. Distribution is scheduled throughout North America, and globally in Latin America, Europe, Asia Paciﬁc, as well as the Middle East and Africa. This global market is currently experiencing an estimated growth of 14% per year and is expected to reach $4.696 billion in sales this year. Umbra Applied Technologies Group Chief Executive Officer, Alex Umbra, commented, "The growth and interest that Ossifix has experienced is unprecedented. With the launch of their additional product suites coming later this year, Ossifix will be a disrupting force within a niche but significant market segment”. Ossifix Orthopedics will continue to meet with hospital systems, surgical centers and orthopedic surgeons across the U.S. with international sales slated to begin later this year. For more information about Ossifix Technologies go here: https://ossifixtech.com/ About Umbra Applied Technologies Group, Inc. The firm is located in Tampa Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details Umbra Applied Technologies Group, Inc. info@uatgroup.com

March 17, 2023 08:00 AM Eastern Daylight Time

American Center for Cures Co-Founder Appointed by President Biden to National Cancer Advisory Board

The American Center for Cures

The American Center for Cures (ACC) today announced its long-time partner and co-founder Dr. Richard Boxer has been selected by President Joseph Biden to the National Cancer Advisory Board. In this role, Dr. Boxer will use his years of medical expertise to help guide the Director of the National Cancer Institute in the development of the organization’s national cancer research. Along with venerated entrepreneur Lou Weisbach, Dr. Boxer co-founded the ACC as a bipartisan initiative that aims to unite medicine, science, pharmaceuticals, business, and government to seek out new treatments and cures for Alzheimer’s, diabetes, Parkinson’s, mental diseases, many forms of cancer, and several others. “Richard Boxer and I have worked together on this important endeavor for more than a decade. It’s an honor to see him elevated to the National Cancer Advisory Board,” said Lou Weisbach, CEO and Co-Founder of ACC. “I’ve been working in a bipartisan way with leaders of both parties and the quote from Tom Price, former Secretary of Health, tells you all you need to know about our mission: ‘When this plan is approved it will rival the greatest achievements in US history and offer the sense of urgency that all American families yearn for and deserve when battling disease.’” Dr. Boxer, a UCLA Clinical Professor and Co-Founder of the American Center for Cures added: “I’ve dedicated my professional career to compassionate and uncompromising care for cancer patients and educating the public and the medical community and preventing and curing disease is a critical single issue that all Americans can agree on. As a practicing urologist treating cancer patients and cancer survivor myself, the mission of the ACC and my role in its success is very personal.” Dr. Boxer, a Clinical Professor at the David Geffen School of Medicine at UCLA, himself a three-time cancer survivor, has been practicing medicine for 44 years, caring for more than 7,000 patients with cancer and tens of thousands of patients with other illnesses. He represented the U.S. at the World Health Organization as a private citizen, a finalist for Surgeon General of the United States in both a Democratic and Republican Administration, and he was recently on the Board of Directors of the American Society of Clinical Oncology Conquer Cancer Foundation. Dr. Boxer has published nearly 100 journal articles and book chapters on medical research and has also written extensively on health policy in national press outlets. He helped create the initial clinical protocols for telemedicine, becoming the Chief Medical Officer of numerous telemedicine companies. In April 2021, he was awarded the Distinguished Alumni Award by the University of Wisconsin’s Medical School, its highest honor. “This is a critical single issue that all Americans can agree on, whether they be black or white, rich or poor, Democrat or Republican,” declared Weisbach. “With kudos to all medical breakthroughs of the past, we still haven’t gotten the job done in a business-like fashion as a nation when it comes to prevention and cures. That ends today. We are not asking congress or both parties to move forward on this initiative, we are insisting that it be passed unanimously. This issue impacts all 335 million Americans in the same way, including everyone in The White House, as well as members of Congress and their families. If we cannot unite on this issue as Americans, then I submit there are no issues on which we can unite.” About American Center for Cures The American Center for Cures (ACC) initiative is a fully funded mission to prevent, treat or cure diseases that plague every American family. The initiative will be funded by the sale of $750B bonds by the Federal Reserve, providing the capital needed to accelerate the current trajectory of medicine. Annual interest will be paid through the licensing of new compounds and drugs to pharmaceutical companies. The principal will be repaid by savings provided to the United States Government through successes in the areas of prevention and cures. The ACC business model will cost the government and taxpayers nothing, making this the single most impactful investment on behalf of the American people in the nation’s history. For more information, please visit https://theamericancenterforcures.org. Contact Details Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website https://theamericancenterforcures.org

March 15, 2023 02:33 PM Eastern Daylight Time

Spring Cleaning Your Brain Health

YourUpdateTV

Spring is almost here and it’s time to clear out the cobwebs and rethink and re-energize your health and wellness routines for the rest of the year. And while many people focus on physical health, it’s also important to think about your mental and emotional well-being. Recently, Nutrition Expert, Mia Syn, teamed with The Vitamin Shoppe on a nationwide satellite media tour to help boost your health and wellness going into Spring. A video accompanying this announcement is available at: https://youtu.be/2NqDH4Uah-A Staying Hydrated Brain health is a critical piece of your overall health that can not only improve your physical health but can also create positive cognitive and emotional impacts that contribute to overall well-being. One thing many people forget about is proper Hydration. Hydration is essential as it assists blood flow and oxygen to the brain, which helps both brain and memory function. Waterdrop is a great way to drink more water and reach your daily hydration goals. Made from natural plant and fruit extracts for flavor, Waterdrop cubes are just dropped into a glass of water and provide you with energy from caffeine, plus essential vitamins and hydration – all without sugar. They come individually wrapped so you can bring them anywhere and just drop into your refillable water bottle! Impact of Stress on the Brain Stress can have many effects on brain health and our overall health, including physical symptoms like headaches and pains, but also things like memory, mood, anxiety levels, and social behaviors. Solaray’s SHARPMIND line of supplements is formulated with clinically studied nutrients, adaptogens and nootropics, to support mental and emotional well-being. The SHARPMIND Mood formula is formulated with holy basil and reishi mushrooms to support stress and mood levels. SHARPMIND Focus has Lion’s Mane mushrooms and Bacopa to support memory and cognitive health. There are also other unique formulas for sleep, energy, and stress, to support different areas of your well-being. Optimizing Physical and Mental Performance Like other parts of your body, your brain needs proper nutrition to perform at its best whether at work, home, or on-the-go. So, whether you want to improve cognitive function, or simply feel healthier and more energetic, we need to make sure our brains are getting what they need. Focus Factor from Synergy CHC contains a clinically-tested and patented combination of neuro-nutrients plus vitamins and minerals. This formula not only helps boost your memory and focus, but it can also replace your everyday multivitamin, making it an excellent 2-for-1 supplement option to help optimize your performance throughout the day. Sleep and Aging Many of us struggle to get the quality sleep we need, and after a night of tossing and turning, we often lack the energy, confidence, and clear thinking we need to accomplish our goals. Somnapure Sleep Gummies from Force Factor can help. Their 100% drug-free, non-habit-forming formula contains a 10 mg dose of melatonin which helps you relax before bed, so you can fall asleep faster and stay asleep longer. And finally, as people age, our physical and mental performance may require more support. But there are ways for us to address these deficits and maintain our edge. Forebrain Advanced from Force Factor is formulated with brain-boosting herbs and advanced nootropics that can help you achieve better cognitive performance and improve memory and recall. For more information, visit vitaminshoppe.com About Mia Syn Mia Syn, MS, RDN is a nationally recognized nutrition expert and founder of Nutrition by Mia, a popular online wellness destination frequented by millions of readers around the globe. She holds a Master of Science in human nutrition from Columbia University and has been featured by dozens of major media outlets including Women's Health Magazine, Cosmopolitan and SHAPE. As one of the most recognized and trusted young nutritionists in the country, she has helped hundreds of her clients and millions of her readers lose weight, improve their health and develop better sustainable eating habits for life. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 15, 2023 09:37 AM Eastern Daylight Time

Video

How Technology Is Helping Frontline Workers Get Healthy Food

Blendid

By Faith Ashmore, Benzinga Interested in investing in Blendid’s campaign? Click here to get started! Consumer demand for healthy food options has skyrocketed in recent years; COVID-19 put health on many people's minds and changed consumers’ standards as well as their priorities. A recent study showed that 54% of all consumers care more about the healthfulness of their food in 2020 than they did in 2010. Healthfulness is now the biggest determining factor in purchasing food, even more than taste and price. However, healthy food is not always accessible, especially for frontline workers or individuals who work overnight shifts. While McDonald’s and other fast-food chains of the world operate on a late-night or 24-hour model, you would be hard-pressed to find a health food store that is open late and can serve populations of workers like nurses, truck drivers, and more. For these late-night workers, their only real option is often unhealthy fast-food, and even fast food has become less of an option in the post-pandemic world. COVID-19 and labor shortages have resulted in fewer retailers with 24/7 service. Because of this, more and more previously 24/7 establishments like McDonald’s are closing early and leaving overnight shift workers without any options. Blendid, a robotic and AI-enabled food automation solution company, is creating clever solutions to this problem. The company has seen firsthand the success of a fully autonomous robotic kiosk for smoothies. Their kiosks operate in universities, travel centers, retail stores and hospitals across the country. The kiosks can operate 24/7, which gives consumers access to healthy and affordable food around the clock while the company is able to maintain low operational costs. Blendid’s 24/7 kiosks provide healthy alternatives for workers when they need them most. The company has kiosks at two Love’s Travel Stops in California and a location at Grady Memorial Hospital in Atlanta, among others. A truck driver who frequents one of the Love’s Travel Stops shared, “That juice-making robot is awesome. I loved watching it. Truck drivers need raw nutrition." The company’s robotic model enables fresh food to be offered where it previously hasn’t been and during all hours of the day, not just traditional daytime working hours. Not to mention, all Blendid locations offer the capability of ordering ahead and customizing ingredients to fit customers’ needs and nutritional wants. The company has seen a 267% revenue increase year-over-year which is unsurprising given the consumer demand for healthy and sustainable food. Not only is the kiosk model contactless, but also being open 24/7 increases the accessibility of healthy food. For college students or late-night workers, who typically have limited access to healthier foods, Blendid is giving people options they didn’t previously have. If projections are to be believed, the food robotics industry is only going to continue to grow. The global market for food robotics was estimated at $2.1 billion in 2022, and the market is projected to reach $4B by 2026. Companies like Blendid will be instrumental in the industry by providing unique experiences and options for consumers on the go. Technology is helping bring healthy and affordable food where people need it most. Blendid is currently hosting a raise to further expand its ingenious concept. The company is currently working on expanding to 10 additional geographies in the near future and has 500+ kiosks in contract. Previously, it raised more than $26 million which translated into significant revenue growth. Blendid could be well-positioned as an industry leader and seems eager to meet the consumer demand for on-the-go 24/7 healthy food. Interested in investing and being a part of their growth story? Click here to read more about Blendid’s raise and how to invest! This article was originally on Benzinga here. Sunnyvale-based Blendid is revolutionizing the future of food service with its proprietary food automation platform (foodOS™), which efficiently and safely prepares and serves a range of healthy, fresh, and delicious food. A pioneer of the future of food service, Blendid's first concept in the market is an autonomous, contactless kiosk that uses robotics, machine vision, artificial intelligence, and healthy ingredients to create delicious smoothies that are customized to meet the unique health and dietary preferences of each consumer. Founded in 2015 by seasoned Silicon Valley entrepreneurs Vipin Jain, Venki Avalur, and Vijay Dodd, Blendid is improving the consumer experience by offering safe, cost-effective, and personalized food on-demand, while also reducing complexities and costs for the operators. Blendid has raised more $20M to date from a mix of venture and crowdfunding investors and is currently raising its Series B investment round. Visit www.startengine.com/blendid for more information and to invest in the future of food service automation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17b disclosure linked in the campaign page for more information. Contact Details Erica Camilo 344130@email4pr.com Company Website http://www.blendid.com

March 15, 2023 09:00 AM Eastern Daylight Time

Aptamer Group "anticipating higher revenues" in its second half

Aptamer Group PLC

Aptamer Group PLC (AIM:APTA) CEO Dr Arron Tolley speaks to Proactive's Thomas Warner following the release of the company's interim results. Dr. Tolley gives his take on how the business performed during the first half of its financial year, adding that he is "anticipating higher revenues" in the second half. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 15, 2023 07:32 AM Eastern Daylight Time

Video

VinBrain becomes NVIDIA Inception Premier Member

Vingroup

HANOI, VIETNAM - Media OutReach - 14 March 2023 - VinBrain has become a Premier member of NVIDIA Inception, a global program that provides cutting-edge startups with access to accelerated computing resources and more. By teaming up with NVIDIA, VinBrain is poised to transform HealthTech innovation in Southeast Asia, building on its previous successful collaborations with Microsoft and Stanford University. As a Premier member of NVIDIA Inception, VinBrain has the advantage of being an early adopter of NVIDIA's latest hardware innovations. Moreover, VinBrain receives ongoing technical support by regularly meeting with R&D experts, empowering the company to design and train advanced AI models and seamlessly integrate AI systems into clinical workflows. With this capability, VinBrain is better equipped to serve hundreds of hospitals across Vietnam, the United States, and Southeast Asian nations with optimal efficiency. VinBrain's AI product suite, including DrAid™, AIScaler™, and SenMe™ (aka AIviCare™) is now featured on the NVIDIA Accelerated Apps Catalog. “ We are thrilled to become a Premier member of NVIDIA Inception,” said Steven Truong, CEO of VinBrain. “ VinBrain has collaborated with Microsoft Corporation on data sharing, cross-validation, product research and development, and with Stanford University on in-depth research and data use, including hundreds of thousands of shared medical images. Continuing collaboration with NVIDIA in the hardware field will create a strong foundation for VinBrain to enhance quality, efficiency, and accessibility of healthcare services, bringing the best value of AI to provide effective support for patients and doctors." VinBrain has committed to NVIDIA's cutting-edge tech solutions from the outset, relying on the NVIDIA Clara healthcare platform, MONAI open-source framework, and NVIDIA NeMo framework for training, customizing and deploying generative AI models. Likewise, VinBrain has used NVIDIA DGX SuperPOD-powered AI supercomputing to develop computer vision solutions for medical imaging, intelligent video analytics, automatic speech recognition, natural language processing, and text-to-speech, resulting in 100x faster model training than with CPU only. “ VinBrain provides impactful solutions for many hospitals globally and supports healthcare professionals to augment their workflows and deliver precision radiology,” said Renee Yao, Global Healthcare AI Startups Lead at NVIDIA. “As a Premier member of NVIDIA Inception, VinBrain will work with NVIDIA to improve healthcare and precision medicine.” Healthcare has notably been one of the emerging industries in NVIDIA’s Inception, which now boasts over 1,300 healthcare startups. Steven Truong will speak at an exclusive Healthcare AI Council as part of NVIDIA GTC, a global AI conference running March 20-23, 2023 in San Francisco, US. He will share his thoughts on the future of innovation in the healthcare and life sciences industry and discuss how to collaborate globally and bring bigger impacts to improve patient outcomes and efficiency for doctors’ workflows. About VinBrain As a 4-year-old startup, Invested by Vingroup, the biggest conglomerate in Vietnam, VinBrain has a mission to infuse AI and IoT to improve people's lives and productivity. The company has developed over 300 AI models that process medical images and medical reports including X-ray, CT, MRI and medical reports data from a dataset of over 2.5 million images and big data of text. The comprehensive AI platform, DrAid™, has been deployed in over 100 hospitals in Vietnam, Myanmar, New Zealand, and the US.To learn more, visit the VinBrain website: https://vinbrain.net/ Contact Details Media Contact v.chidqd1@vingroup.net Company Website https://vinbrain.net/

March 14, 2023 09:30 AM Eastern Daylight Time

Image

New Policy to Allocate Donor Lungs Takes Effect

United Network for Organ Sharing

Earlier this month, United Network for Organ Sharing (UNOS) launched a new lung allocation policy that will increase equitable access for patients who are in greatest need of a lung transplant while decreasing the overall number of patient deaths on the national waitlist. UNOS is the non-profit that contracts with the federal government to serve as the nation’s Organ Procurement and Transplantation Network (OPTN). Developed with the help of the Massachusetts Institute of Technology (MIT), RTI International (RTI) and the Scientific Registry of Transplant Recipients (SRTR), this policy is the first to use continuous distribution, which will become the standard for kidneys, pancreases, hearts, livers and other types of organ transplants in the future. This new, dynamic framework relies on a more holistic view of each patient, dissolves rigid boundaries that exist in the current, category-based system, and ensures that no single factor determines a patient’s priority on the waitlist. Donor lungs will now be allocated based on a unique composite score developed for each patient. This score will be based on a variety of factors, including illness severity, biology, expected time of life after transplant and more. “This innovative new system will be more equitable and patient-focused,” said Marie Budev, D.O., M.P.H., who serves as chair of the OPTN Lung Transplantation Committee, which spearheaded the policy development. “Instead of considering the many factors that define a candidate's unique need for an organ sequentially, we can now consider them all simultaneously for each patient.” Researchers from MIT's Sloan School of Management assisted the committee in developing the continuous distribution framework by applying artificial intelligence (AI) and machine learning to evaluate the effectiveness of millions of different policy scenario options. RTI contributed analysis, and the SRTR performed simulation modeling to validate results, remaining involved throughout the policy framework’s implementation. “Continuous distribution is a generational change in the field of organ allocation,” said James Alcorn, senior policy strategist at UNOS. “We were able to build a system that’s much nimbler than before, allowing us to identify issues and implement solutions much more quickly in the future.” As part of the policy development process, a diverse group of nearly 200 individuals representing a wide range of experiences and perspectives in donation and transplant, including patients, took part in an exercise where they shared what factors they considered most important when developing the composite score. Similar to how one turns a dial, the committee can now easily adjust the weights on the scale to further optimize the allocation system when policy changes are approved. “Take pediatric priority, for example. When we identify a certain patient group that is not appropriately prioritized, we can quickly identify the attribute they share in the system, and then adjust its weight to improve the entire system,” Alcorn said. Statistical modeling predicts that the new lung policy will not only reduce the number of patients who die waiting for a lung transplant but will also increase access to transplants for patients in need, including those with the most severe illness. A recent study by the Cleveland Clinic, in partnership with the SRTR, found that across all modeling scenarios, “the system led to improved overall measures of equity” when compared to the previous system. UNOS has hosted multiple webinars and provided resources to support patients, physicians and other donation and transplant professionals during the transitional phase. To date, hundreds of individuals have attended these public webinars. Additionally, UNOS has created patient materials that address questions for candidates on the waiting list. The OPTN Board of Directors unanimously approved the policy in December 2021. The OPTN Lung Transplantation Committee will actively monitor the new lung policy and, if needed, make recommendations for additional improvements. Work to transition all other organ types to the continuous distribution framework is proceeding, with kidney and pancreas policies anticipated next. About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

March 14, 2023 09:17 AM Eastern Daylight Time

Video

The LED Lighting Market’s Growth Is In Double Digit Rates And Order Books Are Growing – Applied UV (NASDAQ: AUVI) Sub Just Secured A Multi-Million Order From A Leading Luxury Developer

Applied UV, Inc.

By Ernest Dela Aglanu, Benzinga The global LED lighting market, thanks to players like Applied UV Inc. (NASDAQ: AUVI), is witnessing significant growth. The market size was valued at $68.9 billion in 2022 and is projected to reach $264.08 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 17.6% during the forecast period. One of the primary drivers of the market’s growth is the rising need for energy-efficient light sources. LED lights consume less energy and have a longer lifespan compared to traditional lighting sources such as incandescent bulbs, fluorescent tubes, and halogen lamps. As a result, LED lights are gaining popularity in both the residential and commercial sectors, leading to a surge in demand. Additionally, increasing environmental awareness and conscious efforts toward sustainability are also contributing to the growth of the LED lighting market. LED lights are free from toxic materials such as mercury that pose a threat to the environment and human health. Therefore, they are considered eco-friendly and have become the preferred choice for lighting solutions in many sectors. Governments worldwide are implementing favorable policies to encourage the adoption of LED lighting. In many countries, subsidies, incentives, and tax benefits are offered to consumers who opt for LED lights. These government initiatives have resulted in increased awareness and adoption of LED lights, further fueling the market’s growth. The increasing LED lighting adoption and growth of the market is good news for companies like Applied UV, Universal Display Corporation (NASDAQ: OLED), Energy Focus Inc. (NASDAQ: EFOI), and LSI Industries Inc. (NASDAQ: LYTS) that are developing products to meet growing demand. Within the industry, Applied UV seems to have carved a niche for itself as a provider of proprietary surface and air disinfection technology focused on Improving Indoor Air Quality (IAQ), specialty LED lighting, luxury mirrors and commercial furnishings – all of which serves clients globally in both the commercial and retail segments. The company’s products address needs in the healthcare, hospitality, food preservation, cannabis, education, and winery vertical markets. Applied UV has established strategic manufacturing partnerships and alliances, including Canon, Acuity, Johnson Controls, USHIO, Siemens, Grainger, and a global network of 64 dealers and distributors in 52 countries, offering a complete suite of products through its two wholly owned subsidiaries — SteriLumen Inc. and MunnWorks LLC. Multi-Million Dollar Order From Premier Developer Applied UV ’s growth and recent announcement of purchase orders totaling $4.55 million could interest investors and watchers of the LED lighting industry. The company recently revealed that its wholly owned subsidiary LED Supply Co. had secured a multi-million dollar purchase agreement from an unnamed premier co-living rental property developer The X Company (“X Co.”). The purchase orders consist of $2.67 million received and the balance of $1.88 million assured by the end of the second quarter. LED Supply Co. will provide back-lit mirrors, LED lighting and control systems for X Co.’s growing billion-dollar portfolio of properties. The orders will be fulfilled by LED Supply Co., in partnership with MunnWorks, who will manufacture the backlit mirrors in its newly acquired 100,000-square-foot Brooklyn, NY facility. “Having access to the MunnWorks’ high-end U.S.-made decorative backlit mirrors and case goods, at competitive prices, allows us to provide a better-quality product to our residents while staying within our allotted budget on a project,” Ben Brichta, Partner at X Co., said. The premier co-living rental property developer reports that it is active in six markets, with 5,000 beds in its current portfolio and over $1 billion in construction activity. The company says it is fully integrated — able to acquire, design, build and operate its real estate assets. X Co. buildings offer a high level of amenities and resident experiences in their unique combination of private rentals, co-living suites and co-working spaces. They also offer residents an unconventional club environment supporting the growing work-from-home segment with a state-of-the-art gym and fitness studios, social activities and dramatic shared spaces. The orders more than double X Co.’s previous orders with LED Supply Co. and expands them to include backlit mirrors supplied by Applied UV subsidiary MunnWorks, with subsequent orders planned for later this year. The joint order is the first in what the company expects to be many collaborative sales efforts forecasted as part of the merger of Applied UV, LED Supply Co. and PURO Lighting announced in January of this year. This article was originally published on Benzinga here. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/

March 13, 2023 09:15 AM Eastern Daylight Time

1 ... 50 51 52 53 54 ... 147